The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.
 
Tanya Jindal
No Relationships to Disclose
 
Cindy Jiang
No Relationships to Disclose
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)
 
Fady Sidhom
No Relationships to Disclose
 
Albert Jang
Honoraria - RealTimeCase
 
Dimitra Rafailia Bakaloudi
No Relationships to Disclose
 
Ishita Narula
No Relationships to Disclose
 
Salvador Jaime-Casas
No Relationships to Disclose
 
Michael Glover
No Relationships to Disclose
 
Amanda Nizam
Honoraria - Aptitude Health; ASCO; Cleveland Clinic; Doximity; IntegrityCE; Mashup Media (GU Oncology Now); MECC Global Meetings; Targeted Oncology
Consulting or Advisory Role - Astellas Pharma; AVEO; EMD Serono/Merck; Mashup Media (GU Oncology Now); Medscape; Pfizer/Seagen
Travel, Accommodations, Expenses - ASCO; Mashup Media; MECC Global Meetings
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Mehmet Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Sumit Shah
Honoraria - Janssen
Consulting or Advisory Role - Grand Rounds/Included Health; Natera
Research Funding - Genentech
 
Abhishek Tripathi
Consulting or Advisory Role - AADi; Bayer; Deka biosciences; Exelixis; Gilead Sciences; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Sanofi
 
Petros Grivas
Consulting or Advisory Role - Abbvie; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; CG Oncology; Daiichi Sankyo; EMD Serono; Fresenius Kabi; Gilead Sciences; ImmunityBio; Janssen; Merck; Pfizer; Replimune; Roche; Strata Oncology
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Mirati Therapeutics (Inst); QED Therapeutics (Inst)
 
Jason Brown
Honoraria - AstraZeneca
Consulting or Advisory Role - EMD Serono; Johnson & Johnson/Janssen; Pfizer
Speakers' Bureau - EMD Serono
Research Funding - Bicycle Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst)
 
Arnab Basu
Honoraria - Cardinal Health; Eisai; Gilead Sciences; Natera
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; EMD Serono; Seagen
Speakers' Bureau - Eisai
Research Funding - Astellas Pharma (Inst); AVEO (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Natera (Inst)
 
Matthew Campbell
Honoraria - Axdev; Curio Science; Eisai; Exelixis; MJH Life Sciences; Seagen; Targeted Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; Exelixis; SeaGen
 
Ajjai Alva
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Janssen; Merck Sharp & Dohme; Mirat Therapeutics; Progenics; Prometheus; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Vadim Koshkin
Consulting or Advisory Role - Bicycle Therapeutics; Clovis Oncology; Gerson Lehrman Group; Guidepoint Global; Janssen; Loxo; MSD; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology (Inst); Curium Pharma (Inst); Endocyte (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Seagen (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma